Amarin Corp Plc (AMRN)

[tucaman]

What about the Novartis/Sandosz deal? Makes even more sense to me.

Question: If Novartis (or any other BP with a big generics arm) buys AMRN; could they immediately start marketing Vascepa under their generic Sandosz brand? Or would they need to honour the 180 days exclusivity for generic Vascepa. I don't think so, as it would still be branded Vascepa, simply at a lower price than for generics. Any opinions?

If so one could actually still most if the US R-IT TAM and price Generics out of the market. While Europe could be developed as a branded market. Wouldn't be to bad of a deal for a BP moving quickly.

Let's hope that rumor spread by someone the other day that management is contemplating a buyout at 13-20$ to some has some merits. Though that would require JT to finally take some action and stand up to his words re shareholder value (doubtful).